Navigation Links
JAZZ PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2013 FINANCIAL RESULTS
Date:8/6/2013

d to pro forma net sales of $12.4 million in the same period of 2012.  "Other" includes products acquired in the EUSA Pharma and Azur Pharma transactions that are not mentioned above. 

Operating Expenses and Other Operating expenses for the second quarter of 2013 increased to $131.2 million compared to $84.8 million for the second quarter of 2012.  Operating expenses increased over the prior year period for the following reasons:

  • Cost of product sales for the second quarter of 2013 was $25.0 million compared to $12.3 million for the same period in 2012.  The increase in the 2013 period was primarily due to higher net sales and a change in product mix. Gross margin for the second quarter of 2013, as a percentage of product sales, was 87.9% compared to 90.0% for the same period in 2012.  Our gross margin percentage in the second quarter of 2013 as compared to the same period in 2012 was lower primarily due to lower gross margins on products acquired as part of the EUSA Pharma acquisition.
  • Selling, general and administrative ("SG&A") and research and development ("R&D") expenses for the second quarter of 2013 totaled $86.8 million on a GAAP basis compared to $59.5 million for the same period of 2012.  The increase reflected higher headcount and related expenses due primarily to the expansion of our business and an increase in the fair value of contingent consideration related to the EUSA Pharma acquisition, partially offset by lower transaction and integration costs.  Adjusted SG&A and R&D expenses for the second quarter of 2013 totaled $70.6 million compared to $44.0 million for the same period in 2012.
  • Intangible asset amortization for the second quarter of 2013 was $19.4 million compared to $13.0 million for the same period in 2012.  The increase was primarily related to amortization of intangible assets acquired as part of the EUSA Pharma acquisition.
  • Second quart
    '/>"/>

    SOURCE Jazz Pharmaceuticals plc
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine technology :

    1. Cumberland Pharmaceuticals Reports Second Quarter Financial Results
    2. Inovio Pharmaceuticals Responds to Market Activity
    3. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
    4. Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Bausch + Lomb
    5. Avanir Pharmaceuticals to Participate in Two Conferences in August
    6. Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
    7. AcelRx Pharmaceuticals to Present at Canaccord Genuity 33rd Annual Growth Conference
    8. Isis Pharmaceuticals Reports Data From a Phase 2 Study of Isis-CRP Rx in Patients with Rheumatoid Arthritis
    9. Intercept Pharmaceuticals to Present at the Wedbush Securities Life Sciences Management Access Conference
    10. GW Pharmaceuticals Announces Results of MS Spasticity Study Confirming Sativex Has No Long-Term Negative Effect on Cognition
    11. GW Pharmaceuticals plc Reports 2013 Third Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... , July 11, 2014  Australian drug delivery company, ... it has raised A$19.3 million via a placement of ... , the U.S., Asia ... from a share purchase plan (SPP) to be offered ... be made in two tranches. "This capital ...
    (Date:7/11/2014)... 11, 2014 On Thursday, ... 0.52%, the Dow Jones Industrial Average finished the day 0.42% ... down 0.41%. The losses were broad based as eight out ... 500 Health Care Sector Index ended the day at 711.88, ... last one month. Investor-Edge has initiated coverage on the following ...
    (Date:7/11/2014)... 2014 According to a new ... Market (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) - ... 2013-2019" the global endoscopy devices market was valued at ... grow at a CAGR of 6.8% from 2013 to ... billion in 2019. Browse the full Endoscopy ...
    Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6
    ... levels following 4 weeks of, treatment with R7128 1500mg and Pegasys(R) plus ... tolerability comparable to ... - Conference Call Scheduled for 4:00PM ET Today -, PRINCETON, N.J., ... of a 4-week Phase 1,clinical trial to evaluate two oral dose levels ...
    ... Duration of ... Neutropenia- ... Jan. 7 Maxygen, Inc.,(Nasdaq: MAXY ) today announced positive progress in ... the trial include the following:, -- Patients in the initial 10 ...
    Cached Medicine Technology:Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 2Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 3Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 4Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 5Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 6Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF 2Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF 3Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF 4
    (Date:7/11/2014)... Recently, Fadhits.com, the distinguished wedding dress manufacturer and retailer, has ... To bring more benefits to worldwide clients in this great ... for these brand new items. Clients can enjoy thwe special ... says gladly, “We are happy to announce such a promotion. ... new and old customers and strengthen our relationship with them. ...
    (Date:7/11/2014)... 2014 Fadhits.com, the distinguished wedding dress ... of lace holiday dresses . To top it ... offered at discounted prices, up to 65% off. Clients ... this special offer. , Fadhits.com is devoted to ... dresses for the global clients. All its items come ...
    (Date:7/11/2014)... prescribed exercise as medicine, according to a QUT ... is essential to reducing the risk of death ... QUT,s Institute of Health and Biomedical Innovation, said ... and mental health, health professionals should be prescribing ... Anderson and QUT,s Dr Charlotte Seib co-authored a ...
    (Date:7/11/2014)... research from UC San Francisco shows that an ... Project helps women living with HIV disclose their ... and the safety and quality of their relationships., ... first author, Edward L. Machtinger, MD, director of ... percent of our patients are on effective antiretroviral ...
    (Date:7/11/2014)... that people who have grown up on a farm ... urban counterparts to develop the most common inflammatory bowel ... have recently been published in the European Journal ... we can now see that not only allergic diseases, ... on the environment we are exposed to early in ...
    Breaking Medicine News(10 mins):Health News:Promotion for Kids Prom Dresses Now Provided at Fadhits.com 2Health News:Elegant Lace Holiday Dresses Released by Fadhits.com 2Health News:Exercise is the best medicine: QUT study 2Health News:'Expressive therapy" intervention assists women living with HIV 2Health News:Growing up on a livestock farm halves the risk of inflammatory bowel diseases 2
    ... support efforts to reduce air pollution, especially diesel exhaust ... studies from Europe demonstrate the health damage done by ... engines. , An 11-year period of improving air quality ... air in Europe, produced measurable benefits in lung function ...
    ... healthy lifestyle drives new store openings, PITTSBURGH, Dec. ... new resolution or two. For GNC, it means more ... is expected to rise steadily,through 2012, according to the ... to once again expand its store base and overall,business: ...
    ... Ky., Dec. 5 Ventas, Inc. (NYSE:,VTR) ... the Executive,Compensation Committee of its Board of ... certain executive officers to encourage their,long-term retention ... to,Raymond J. Lewis, the Company,s Chief Investment ...
    ... Growing price competition from,low-cost manufacturers has been forcing ... profitable growth, which Kalorama Information predicts,will likely come ... pharmaceutical,medical foods, or biomedical device companies -- a ... Healthcare Opportunities for Food Ingredient,Manufacturers., Thousands of ...
    ... still debated, experts say , , WEDNESDAY, Dec. 5 (HealthDay News) ... Wednesday that the cancer drug Avastin should not be used ... close vote, 5-4, the advisers decided the drug,s ability to ... increased risk of blood clots and other cardiovascular troubles among ...
    ... A new white paper,published by The Endocrine ... major new initiatives to ensure effective,broad-based minority participation ... of recommendations to ensure that data from clinical,trials ... The white paper, developed by a special ...
    Cached Medicine News:Health News:Cleaner Air Leads to Healthier Lungs 2Health News:Cleaner Air Leads to Healthier Lungs 3Health News:GNC Franchising Expected to Grow Through 2008 2Health News:Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance 2Health News:Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance 3Health News:Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance 4Health News:Medical Industry Offers Food Ingredient Companies More Than One Billion Reasons to Think Healthy 2Health News:FDA Panel Says No to Avastin for Advanced Breast Cancer 2Health News:FDA Panel Says No to Avastin for Advanced Breast Cancer 3Health News:The Endocrine Society Publishes White Paper Calling for Greater Minority Participation in Clinical Research 2Health News:The Endocrine Society Publishes White Paper Calling for Greater Minority Participation in Clinical Research 3Health News:The Endocrine Society Publishes White Paper Calling for Greater Minority Participation in Clinical Research 4
    The Professional ophthalmoscope has been designed to ensure ultimate control. Lenses, graticules and filters can all be introduced at the touch of a fingertip without the need to pull away from the p...
    ... Sprint Automated Urine Microscopy Analyzer (iQ200 Sprint) ... Series. The analyzer uses digital imaging and ... particles into 12 categories and quantitatively report ... time used to prepare and interpret urine ...
    A flexible hematology platform:, 32 parameters, Automatic result validation, Cytology atlas included, CBC and 5+3 DIFF...
    StarClose Clip Applier, (includes), Clip Applier, 6F Exchange Sheath, 6F Dilator, 0.038 50 cm J-Tip Guide Wire ...
    Medicine Products: